Ba B B, Iliadis A, Durand A, Berger Y, Necciari J, Cano J P
INSERM U 278, Faculté de Pharmacie, Marseille, France.
Fundam Clin Pharmacol. 1989;3(1):11-7. doi: 10.1111/j.1472-8206.1989.tb00025.x.
The kinetics of ethyl loflazepate were studied in patients with various degrees of renal failure. A strong correlation was noted between urinary excretion of metabolite loflazepate and creatinine clearance. In contrast, elimination half-life and total plasma clearance of the sum of loflazepate + descarboxyloflazepate seemed to be independent of the degree of renal impairment. These results indicate the absence of a risk of accumulation of the 2 main and active metabolites of ethyl loflazepate in patients with renal failure.
在不同程度肾功能衰竭患者中研究了氯氟卓乙酯的药代动力学。观察到代谢产物氯氟卓乙酯的尿排泄与肌酐清除率之间存在很强的相关性。相比之下，氯氟卓乙酯+去羧基氯氟卓乙酯总和的消除半衰期和总血浆清除率似乎与肾功能损害程度无关。这些结果表明，肾功能衰竭患者不存在氯氟卓乙酯的2种主要活性代谢产物蓄积的风险。
